secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-08-22T23:59:59+00:00
Accession:  0001193125-24-205350
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences secures shareholder approval for 1-for-25 reverse split effective Aug 28
--------------------------------------------------------------------------------

- Reverse stock split ratio set at 1-for-25; effective Aug 28, 2024, with new CUSIP 34962G 208.
- Stockholders approved amendment to effect reverse split (26.7M for, 2.1M against).
- Amended 2021 Equity Incentive Plan approved (17.3M for, 6.9M against); adds up to 8.5M new shares plus up to 1.1M from prior plans.
- Class I directors elected: Barbara K. Finck, M.D. (18.8M for), Donald A. Williams (15.4M for), Stephen K. Doberstein (15.1M for).
- KPMG LLP ratified as independent auditor for FY2024 with 28.8M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524205350/0001193125-24-205350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524205350/d888554d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-205350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer